By IDSE News Staff
The microbiota-based live biotherapeutic RBX2660 (Ferring) has been proven to be an effective and safe treatment for recurrent Clostridioides difficile infection (CDI) following standard-of-care antibiotics, with a sustained response through six months. This result was seen in new data from the phase 3 PUNCH CD3 clinical trial.
Researchers conducted a randomized, double-blind, placebo-controlled phase 3 study that included a Bayesian primary analysis integrating data from a